MEFV

Three New Articles in the Journal of Pharmaceutical Analysis Demonstrate the Potential of Natural Compounds to Treat Gastrointestinal Disorders

Retrieved on: 
화요일, 11월 28, 2023
Hepatitis, MEFV, Dave's Picks Volume 13, Hope, Pneumonia, Liver, HSP90, Panax notoginseng, Macrophage, Mouse, Journal, Colitis, Metabolism, Ulcerative colitis, Ethanol, GI, NLRP3, SNZ, ALD, UC, JPA, Pharmaceutical industry

XI'AN, China, Nov. 28, 2023 /PRNewswire/ -- Chronic gastrointestinal (GI) disorders are becoming increasingly common throughout the world, but many of them still lack effective treatment. Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases. The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine. 

Key Points: 
  • Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases.
  • The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine.
  • The article was available online in July 2023 and published in Volume 13, Issue 9 of JPA in September 2023 .
  • Moreover, Rk2 also restored intestinal barrier function by enhancing NLPR6 signaling in the intestine, demonstrating its multifaceted therapeutic potential.

ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Retrieved on: 
수요일, 10월 4, 2023
Heart, ASC, Tissue, MEFV, University, Microbiology, Inflammasome, Leonard M. Miller School of Medicine, AIM2, Serum, Associate professor, Neurosurgery, Traumatic brain injury, Bacterial conjugation, Brain, TBI, Inflammation, Research, CNS, EVS, Super Meat Boy, Seminal vesicles, Journal, Patient, Translational research, Invention, Mouse, Paper, Immunology, Therapy, Injury, Physiology, Pharmaceutical industry, Vaccine, Medication, Biophysics, Medicine

Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.

Key Points: 
  • Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of inflammasomes and their associated ASC specks that trigger damaging inflammation and its spread to surrounding tissues.
  • Data indicate that pyrin inflammasome-mediated inflammation induced by TBI contributes to cardiovascular co-morbidities through systemic release of proinflammatory mediators that activate AIM2 inflammasomes in the heart leading to damaging inflammation.
  • “A heightened systemic inflammatory response is often induced after TBI, but the underlying pathomechanisms that contribute to co-morbidities remain poorly understood.